Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., specializes in the research, production, and sales of medical imaging and industrial non-destructive testing equipment, with a significant portion of its revenue coming from overseas due to the depreciation of the RMB [3][4]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and went public on January 22, 2025. It is recognized as a national key high-tech enterprise [7]. - The company's main business segments include medical ultrasound (71.16% of revenue), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and other (1.26%) [7]. Financial Performance - For the period from January to September 2025, the company reported a revenue of 254 million yuan, a year-on-year decrease of 2.90%, and a net profit attributable to shareholders of 88.94 million yuan, down 3.66% year-on-year [8][9]. - As of September 30, 2025, the company's overseas revenue accounted for 55.26% of total revenue, benefiting from the depreciation of the RMB [3]. Market Activity - On January 15, 2025, the company's stock price fell by 3.56%, with a trading volume of 83.72 million yuan and a turnover rate of 5.99%, resulting in a total market capitalization of 10.207 billion yuan [1]. - The stock has seen a net outflow of 7.16 million yuan from major investors, indicating a reduction in holdings over the past two days [4][5]. Product and Industry Insights - The company showcased its innovative veterinary medical imaging products at the 97th WVC annual conference, engaging with industry experts and gaining valuable user insights [2]. - The industrial ultrasound products are primarily applied in non-destructive testing for water and electricity engineering, including pipelines and pressure vessels [2][3].

Core Viewpoint - Mindray Medical experienced a stock price decline of 2.00% on January 15, 2023, with a trading price of 203.60 CNY per share and a total market capitalization of 246.85 billion CNY [1] Group 1: Stock Performance - Year-to-date, Mindray Medical's stock price has increased by 6.90%, with a 0.94% rise over the last five trading days and a 4.51% increase over the last 20 days, while it has decreased by 8.38% over the last 60 days [1] - As of September 30, 2025, Mindray Medical reported a total revenue of 25.83 billion CNY, a year-on-year decrease of 12.38%, and a net profit attributable to shareholders of 7.57 billion CNY, down 28.83% year-on-year [2] Group 2: Financials and Shareholder Information - Since its A-share listing, Mindray Medical has distributed a total of 35.34 billion CNY in dividends, with 25.03 billion CNY distributed in the last three years [3] - As of September 30, 2025, the number of shareholders for Mindray Medical reached 108,800, an increase of 18.86% from the previous period, while the average circulating shares per person decreased by 15.87% to 11,139 shares [2]

Group 1 - The core viewpoint of the news is that Wando Medical's stock has experienced fluctuations, with a recent decline of 2.05% and a year-to-date increase of 10.65% [1] - As of January 15, Wando Medical's stock price is reported at 17.24 yuan per share, with a total market capitalization of 12.121 billion yuan [1] - The company has a primary business focus on the research, manufacturing, sales of imaging medical devices, and imaging diagnostic services, with 90.72% of revenue coming from medical device sales [1] Group 2 - As of September 30, Wando Medical reported a total revenue of 1.189 billion yuan for the first nine months of 2025, reflecting a year-on-year growth of 8.73%, while the net profit attributable to shareholders was a loss of 27.2098 million yuan, a decrease of 123.51% year-on-year [2] - The company has distributed a total of 769 million yuan in dividends since its A-share listing, with 267 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders increased to 27,200, with an average of 25,882 circulating shares per person, a decrease of 1.22% from the previous period [2][3]

Group 1 - The core viewpoint of the news is that Meinian Health has experienced significant stock price increases, with a year-to-date rise of 65.53% and a recent surge of 56.91% over the last five trading days [2] - As of January 15, Meinian Health's stock price reached 8.74 yuan per share, with a market capitalization of 34.211 billion yuan and a trading volume of 3.187 billion yuan [1] - The company primarily operates in health check-ups and management, with 95.67% of its revenue coming from examination services [2] Group 2 - Meinian Health has been listed on the stock market since May 18, 2005, and has a total of 152,000 shareholders as of September 30, 2025, which is a decrease of 11.85% from the previous period [2] - The company reported a revenue of 6.925 billion yuan for the first nine months of 2025, reflecting a year-on-year decrease of 3.01%, while its net profit attributable to shareholders increased by 110.53% to 51.8599 million yuan [2] - In terms of dividends, Meinian Health has distributed a total of 634 million yuan since its A-share listing, with 127 million yuan distributed over the past three years [3]

Core Viewpoint - The company, Dali Kipu, specializes in high-end applications including semiconductor equipment, smart medical devices, military industry, transportation information technology, aerospace, satellite internet systems, and 5G/6G optical communication systems, indicating significant future value potential [1] Group 1: Company Performance - The company aims to increase its revenue following the completion of its fundraising project phase one last year [1] - The company holds a 5.4% share of the global market for RF microwave MLCCs, ranking 6th globally and 1st among Chinese companies according to the "2025 China MLCC Market Competition Research Report" [1]

Group 1 - The core point of the article is that Rongke Technology (300290) experienced a stock price decline of 4.76% to 20.02 yuan, with a total market capitalization of 12.807 billion yuan as of January 13, 2026 [1] - The stock opened at 21.0 yuan, reached a high of 21.15 yuan, and a low of 19.9 yuan, with a trading volume of 1.341 billion yuan and a turnover rate of 10.3% [1] - The company issued a supplementary announcement regarding abnormal stock trading fluctuations, clarifying that the IPO guidance of Super Fusion Digital Technology Co., Ltd. is unrelated to Rongke Technology [1] Group 2 - The company emphasized that the quality assets mentioned in its capital market business plan disclosed in April 2025 pertain to smart healthcare assets and do not involve Super Fusion or computing server assets [1] - The company reiterated that its main business remains focused on smart healthcare, smart cities, and artificial intelligence applications, with no significant changes [1] - The company advised investors to be cautious and aware of investment risks [1]

（文章来源：证券日报） 证券日报网讯 1月13日，荣科科技在互动平台回答投资者提问时表示，公司与超聚变不存在实质性同业 竞争，辽宁智维云的服务器设备销售业务是公司智慧城市业务的重要组成部分，将持续助力公司"智慧 城市+智慧医疗"的战略推进。控股股东将严格履行避免同业竞争承诺，维护上市公司及全体股东利 益，为投资者创造长期价值。 ...

▲南宁市以互联网及信息技术为依托，建设"南宁云医院"平台。 ■本报记者廖欣 罗屹钦 "李奶奶，早上好！我来为您做检查了。"近日，在青秀区中山路东二里一居民家中，95岁的李奶奶躺在床上，护士刘丽霞轻声问候，随后俯身给李奶奶量血 压、消毒、静脉采血，动作娴熟而轻柔。这温情一幕，正是南宁市大力打造"南宁云医院"平台，破解群众就医难题的生动缩影。 随着老龄化进程加快，术后康复、老年照护、慢病管理等需求日益增长。对于行动不便的老人、失能人群和母婴人群来说，出门就医成为一大难题。作为广 西首个"互联网+护理"服务试点城市，自2022年以来，南宁市以互联网及信息技术为依托，建设"南宁云医院"平台，构建涵盖医、护、药的"互联网+健康医 ▶在南宁市中医医院新华院区，妇科副主任医师明珠通过"南宁云医院"平台为市民提供线上问诊服务。 本报记者廖欣 摄 小平台托举大民生。记者从南宁市卫生健康委员会了解到，目前全市有84家医疗机构超3300名医生、超6700名护士入驻"南宁云医院"平台，提供超过180项 线上线下服务。平台按"就近匹配+双模式派单"调度，确保15分钟服务半径覆盖。 "能上门服务的护士，都是经过严格筛选的。"刘丽霞介绍， ...

Core Viewpoint - The healthcare system in Jiangsu has significantly improved during the "14th Five-Year Plan" period, enhancing accessibility and quality of medical services for residents, particularly in community healthcare settings [1][17]. Group 1: Healthcare Accessibility - Jiangsu has focused on strengthening county-level hospitals, with 84.5% of county hospitals upgraded to tertiary hospitals, and 95% of patients now receiving care within their counties [2][3]. - The establishment of 256 internet hospitals aims to provide convenient online medical services, with a target of serving over 50 million people by 2025 [6]. - The implementation of a policy allowing patients to revisit the same department within three days without re-registering has streamlined the healthcare process [6]. Group 2: Quality of Medical Services - Investment of 4.1 billion yuan has been directed towards developing 16 high-level hospitals, enhancing specialized medical capabilities in areas such as lung transplants and critical care [3]. - The introduction of advanced medical technologies, such as the world's first Y-90 microsphere treatment for liver cancer, showcases the integration of cutting-edge procedures into local healthcare [2]. Group 3: Community Health Management - Jiangsu has shifted from single diagnosis to comprehensive health management, exemplified by personalized health services provided by family doctors [3]. - The establishment of 120 chronic disease screening and prevention centers has improved early detection and management of conditions like hypertension and diabetes [4]. Group 4: Elderly and Child Healthcare - The province has implemented priority services for elderly patients, including zero-waiting times for those over 80 years old, enhancing their healthcare experience [5][8]. - The development of a robust pediatric healthcare network allows children to receive timely treatment for common illnesses at local facilities [11]. Group 5: Traditional Chinese Medicine (TCM) - Jiangsu has achieved full coverage of community TCM clinics, with 352 clinics established, reflecting a significant increase in TCM services [14]. - The integration of TCM into the healthcare system has been supported by training programs for local practitioners, ensuring high-quality care is accessible [15][16].

Core Viewpoint - Iwubio's stock price has shown fluctuations, with a recent decline of 2.05%, while the company has experienced a year-to-date increase of 7.80% in stock value [1] Group 1: Stock Performance - As of January 12, Iwubio's stock price was 30.56 CNY per share, with a market capitalization of 16.001 billion CNY [1] - The stock has seen a 1.56% increase over the last five trading days and a 2.86% increase over the last twenty days, but a decline of 0.78% over the last sixty days [1] Group 2: Financial Performance - For the period from January to September 2025, Iwubio reported a revenue of 853 million CNY, reflecting a year-on-year growth of 16.86% [2] - The net profit attributable to shareholders for the same period was 345 million CNY, marking a year-on-year increase of 26.67% [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Iwubio was 32,400, a decrease of 6.22% from the previous period [2] - The average number of circulating shares per shareholder increased by 6.63% to 14,927 shares [2] - The company has distributed a total of 9.13 billion CNY in dividends since its A-share listing, with 317 million CNY distributed in the last three years [3] Group 4: Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the fourth-largest circulating shareholder, holding 5.562 million shares, an increase of 1.4524 million shares from the previous period [3] - New institutional shareholders include Jiashi Huirong Selected Stock A and Penghua Medical Technology Stock A, holding 4.7118 million shares and 4.2986 million shares, respectively [3]